Search results
Results From The WOW.Com Content Network
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. [4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.
Risankizumab, sold under the brand name Skyrizi (/ s k aɪ ˈ r ɪ z i / sky-RIZZ-ee), is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. [6] [7] It is designed to target interleukin 23A (IL-23A). [6] [7] [9] It is given by subcutaneous injection. [6] [7]
Secukinumab inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells. [11] IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in ...
Ustekinumab is used to treat psoriasis. [29] This includes psoriatic arthritis when it affects the skin. [31] [29] It is indicated for the treatment of adult and adolescent patients (12 years and older) with moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy, and adults with active psoriatic arthritis (PsA) alone or in combination with methotrexate.
Guselkumab lowers the release of immune system signalling molecules, increasing the risk of infections from bacteria, viruses, and fungi. [7]The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, [10] joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
In the United States, ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation. [14]
prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin [12] mab: humanized: IL-2: cancer Certolizumab pegol [43] Cimzia: Fab' humanized: TNF-α: Y: Crohn's disease, rheumatoid arthritis, axial spondyloarthritis ...